© Reuters.
On Monday, Jefferies maintained a Buy rating on Veeva Systems (NYSE:) and increased its price target to $270 from the previous $225.
The firm highlighted the company’s financial guidance for fiscal year 2025, citing its operating margin (OM) outlook as a strong point that overshadows a more cautious stance on billings and revenue projections.
Veeva Systems, a cloud-computing company focused on pharmaceutical and life sciences industry applications, recently provided financial guidance that impressed analysts. The firm’s expectation of higher operating income by fiscal year 2025 has been a key factor in the raised price target.
In addition to the financial outlook, a significant customer win added to the positive sentiment. A top 20 pharmaceutical company’s choice to adopt Veeva’s full Clinical Operations suite has been seen as a testament to the market’s inclination towards more integrated solutions. Jefferies expressed confidence in Veeva’s unique position to capitalize on this trend.
Moreover, Veeva’s data products, including Link and Compass, were acknowledged as being in the early stages of development. However, these offerings are anticipated to present significant long-term growth opportunities for the company.
The revised price target of $270 reflects Jefferies’ optimism about Veeva Systems’ future, particularly in terms of its ability to generate higher operating income by fiscal year 2025. The endorsement from a major pharmaceutical client and the potential of emerging data products contribute to the firm’s positive outlook on Veeva’s stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
